The importance of examining antinuclear antibody (ANA) in neurological diseases

Basit Öğe Kaydı
dc.authorscopusid55768701700
dc.authorscopusid6603214291
dc.authorscopusid53881175300
dc.authorscopusid16069377400
dc.authorscopusid14421891700
dc.contributor.authorBarut, Banu Özen
dc.contributor.authorEmre, Ufuk
dc.contributor.authorDemir, A.S.
dc.contributor.authorÜnal, Aysun
dc.contributor.authorTekin, I.
dc.date.accessioned2022-05-11T14:40:14Z
dc.date.available2022-05-11T14:40:14Z
dc.date.issued2013
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nöroloji Ana Bilim Dalı
dc.description.abstractObjective: In neurological clinical practice screening test for ANA (Anti-nuclear antibody) is helpful in the diagnosis of autoimmune diseases which have neurological involvement. ANA investigation tests might be positive both in connective tissue disorders with neurological symptoms, such as Systemic Lupus Erythematosus, Sjogren's disease, Rheumatoid Arthritis and also in neurological diseases in the which autoimmune system is responsible such as Multiple Sclerosis (MS) and Myastenia Gravis. In addition drug usage and older age are the factors which might cause positive results in ANA screening tests. In this study we aimed to investigate the neurological diseases which are associated with postive ANA tests and to understand the efficiency of this screening test in neurological practice. Material and Method: The patients who were followed up in neurology outpatient clinic with positive ANA test were investigated. The medical records of 309 patients with positive ANA results were evaluated. The most common neurological diseases with positive ANA and ANA patterns were determined. Results: The patients who were thought to be demyelinating disease had the highest number of positive ANA results. However, positive ANA results were also found with different and non specific neurological symptoms. Conclusion: As a result of the diagnosis of neurological diseases, positive ANA results might be beneficial in patients with supportive medical history and laboratory findings.
dc.identifier.endpage78
dc.identifier.issn1305-2381
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-84884328640
dc.identifier.scopusqualityQ4
dc.identifier.startpage74
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8913
dc.identifier.volume9
dc.indekslendigikaynakScopus
dc.institutionauthorÜnal, Aysun
dc.language.isoen
dc.relation.ispartofNobel Medicus
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAntinuclear-antibody
dc.subjectAutoimmunity
dc.subjectDemyelinating disease
dc.subjectantinuclear antibody
dc.subjectarticle
dc.subjectclinical practice
dc.subjectdemyelinating disease
dc.subjectfollow up
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectneurologic disease
dc.subjectscreening test
dc.titleThe importance of examining antinuclear antibody (ANA) in neurological diseases
dc.title.alternativeNörolojik hastaliklarda antinükleer antikor (ana) incelemesinin önemi]
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu